|
Everolimus Delays Tumor Progression In Hard-To-Treat Neuroendocrine Tumors, Phase III Study Shows |
|
Τετάρτη, 13 Οκτώβριος 2010 05:00 |
 |
 |
 |
|
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells. At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors. Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine system... (Source: Health News from Medical News Today)
Source: www.medworm.com
|
